Knott David M Jr Boosts Stock Position in MeiraGTx Holdings plc (NASDAQ:MGTX)

Knott David M Jr grew its stake in MeiraGTx Holdings plc (NASDAQ:MGTX - Free Report) by 1,921.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,080 shares of the company's stock after acquiring an additional 90,377 shares during the period. Knott David M Jr owned 0.12% of MeiraGTx worth $579,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets increased its position in MeiraGTx by 142.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company's stock valued at $39,000 after purchasing an additional 5,476 shares during the period. Erste Asset Management GmbH purchased a new position in MeiraGTx during the third quarter valued at approximately $2,795,000. Garden State Investment Advisory Services LLC bought a new position in MeiraGTx in the third quarter worth approximately $1,636,000. State Street Corp lifted its holdings in MeiraGTx by 0.9% during the third quarter. State Street Corp now owns 574,727 shares of the company's stock worth $2,397,000 after buying an additional 5,251 shares during the period. Finally, Barclays PLC boosted its position in MeiraGTx by 107.1% during the 3rd quarter. Barclays PLC now owns 147,827 shares of the company's stock valued at $618,000 after acquiring an additional 76,437 shares in the last quarter. 67.48% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other MeiraGTx news, CEO Alexandria Forbes sold 35,839 shares of the business's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total transaction of $231,878.33. Following the sale, the chief executive officer now owns 1,395,102 shares in the company, valued at approximately $9,026,309.94. The trade was a 2.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Richard Giroux sold 24,000 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.29, for a total value of $150,960.00. Following the completion of the transaction, the chief financial officer now owns 849,947 shares of the company's stock, valued at approximately $5,346,166.63. The trade was a 2.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.40% of the company's stock.

MeiraGTx Stock Down 7.3 %

NASDAQ MGTX traded down $0.45 on Friday, hitting $5.68. The stock had a trading volume of 1,112,832 shares, compared to its average volume of 298,867. The business's fifty day moving average price is $6.83 and its 200 day moving average price is $6.13. The stock has a market cap of $447.90 million, a price-to-earnings ratio of -4.69, a price-to-earnings-growth ratio of 0.37 and a beta of 1.21. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 2.34. MeiraGTx Holdings plc has a 52-week low of $3.85 and a 52-week high of $8.75.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.05%. The business had revenue of $21.39 million for the quarter, compared to analysts' expectations of $1.50 million. Equities research analysts anticipate that MeiraGTx Holdings plc will post -1.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Royal Bank of Canada upped their price objective on MeiraGTx from $11.00 to $13.00 and gave the stock an "outperform" rating in a research note on Monday, March 17th. Chardan Capital reissued a "buy" rating and set a $36.00 price target on shares of MeiraGTx in a research report on Monday, February 24th.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.